(D31) Use of GLP-1RA in People with T1D: Evidence and Practical Considerations

Sunday, August 9, 2026

3:45 PM - 4:30 PM ET

CE: .75 CE

Pharmacology Hours: .75 CE

Overweight and obesity prevalence is increasing among people with T1D. Insulin therapy alone does not help with cardiovascular risk reduction. In this session, we will review recent evidence on the potential use of GLP-1RA therapy for glycemic and metabolic health improvement in people with T1D. We will also discuss practical considerations on how to initiate GLP-1RAs, reduce GI side-effects, and titrate the insulin dose to minimize hypoglycemia. With increasing use of GLP-1RAs in people with T1D, this session helps attendees by providing practical guidance for the safe use of GLP-1RAs in this population.

Learning Objectives:

At the completion of this activity, participants should be able to:

Identify recent publications/evidence with the use of GLP-1RA in T1D.
Describe practical consideration on how to start GLP-1 RA thearpy and titrate insulin therapy.

Disclosure(s):

Viral N. Shah, MD: NovoNordisk, Sanofi, Lilly, Dexcom, Insulet, Medtronic, Abbott, Tandem Diabetes Care,: Consultant / Advisory Board (Ongoing), Research (Ongoing)

Kate Haynes, RN, BSN, CDCES, LDE: No financial relationships to disclose

Primary Presenter(s)

Viral N. Shah, MD (he/him/his)

Professor of Medicine, Division of Endocrinology & Metabolism
Indiana University School of Medicine

Disclosure(s): NovoNordisk, Sanofi, Lilly, Dexcom, Insulet, Medtronic, Abbott, Tandem Diabetes Care,: Consultant / Advisory Board (Ongoing), Research (Ongoing)

Co-Presenter(s)

KH

Kate Haynes, RN, BSN, CDCES, LDE

Clinical Nurse Coordinator- IU Health Diabetes Centers
IU Health

Disclosure(s): No financial relationships to disclose